Results: Sumitomo Pharma Co., Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts

A week ago, Sumitomo Pharma Co., Ltd. (TSE:4506) came out with a strong set of first-quarter numbers that could potentially lead to a re-rate of the stock. It was a solid earnings report, with revenues and statutory earnings per share (EPS) both coming in strong. Revenues were 20% higher than the analysts had forecast, at JP¥108b, while EPS were JP¥28.21 beating analyst models by 37%. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Taking into account the latest results, the current consensus, from the seven analysts covering Sumitomo Pharma, is for revenues of JP¥380.9b in 2026. This implies a considerable 8.5% reduction in Sumitomo Pharma's revenue over the past 12 months. Statutory earnings per share are predicted to bounce 197% to JP¥141. Before this earnings report, the analysts had been forecasting revenues of JP¥370.6b and earnings per share (EPS) of JP¥121 in 2026. There's been a pretty noticeable increase in sentiment, with the analysts upgrading revenues and making a decent improvement in earnings per share in particular.

See our latest analysis for Sumitomo Pharma

With these upgrades, we're not surprised to see that the analysts have lifted their price target 26% to JP¥1,004per share. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Sumitomo Pharma at JP¥1,600 per share, while the most bearish prices it at JP¥430. As you can see the range of estimates is wide, with the lowest valuation coming in at less than half the most bullish estimate, suggesting there are some strongly diverging views on how analysts think this business will perform. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. One more thing stood out to us about these estimates, and it's the idea that Sumitomo Pharma's decline is expected to accelerate, with revenues forecast to fall at an annualised rate of 11% to the end of 2026. This tops off a historical decline of 9.0% a year over the past five years. Compare this against analyst estimates for companies in the broader industry, which suggest that revenues (in aggregate) are expected to grow 3.9% annually. So while a broad number of companies are forecast to grow, unfortunately Sumitomo Pharma is expected to see its revenue affected worse than other companies in the industry.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Sumitomo Pharma following these results. Fortunately, they also upgraded their revenue estimates, although our data indicates it is expected to perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

With that in mind, we wouldn't be too quick to come to a conclusion on Sumitomo Pharma. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Sumitomo Pharma going out to 2028, and you can see them free on our platform here..

You still need to take note of risks, for example - Sumitomo Pharma has 3 warning signs (and 2 which shouldn't be ignored) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.